Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- Postmenopausal women \>40 years of age experiencing a minimum of 7 to 8 moderate to severe hot flushes per day or 50 to 60 moderate to severe hot flushes per week~Exclusion Criteria:~* The usual exclusion criteria for hormone therapy apply~* Intake of medications other than hormones affecting hot flushes

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5mg DRSP / 0.5mg E2 (BAY86-4891) (Type: EXPERIMENTAL): One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891) (Type: EXPERIMENTAL): One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
- Estradiol (E2 0.3mg) (Type: EXPERIMENTAL): One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).